Navigation Links
Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
Date:3/7/2012

(March 7, 2012) HOBOKEN, NJ Half the population experiences menopause, and for those women, it is a condition they will experience for approximately one third of their lifetime. Alternative or natural remedies are an easy, effective way to improve signs and symptoms linked to the menopausal transition, without side effects. Natural supplement Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, was found to significantly improve signs and symptoms of menopause in a recent clinical trial published in Panminerva Medica.

The study was conducted at Pescara University and examined 70 perimenopausal women, aged 40-50 years. Perimenopause is the term used to describe the menopause transition years, typically the years before and after the final menstrual period. Participants were assigned to a placebo or test group. The test group was given 100 mg of Pycnogenol per day (50 mg taken twice daily), over a period of eight weeks. Participants' menopausal symptoms were evaluated by a scoring system, based on a total of 33 common signs and symptoms, using values ranging from zero (absent) to a maximum of four (very serious). Oxidative stress levels were evaluated by measuring capillary blood plasma free radicals from a drop of capillary blood from the finger tips.

The study found that:

  • Pycnogenol substantially improved perimenopausal signs and symptoms including hot flashes, night sweats, mood swings, irregular periods, loss of libido and vaginal dryness after eight weeks of treatment, as judged by patients' scores, showing a decrease from an average of 2.67/4 to 1.45/4
  • Pycnogenol effectively decreased the severity of hot flashes, decreased bloating and improved irregular heart beat and improved digestive problems
  • Menopausal symptoms categorized under "pain" improved significantly with the group taking Pycnogenol
  • Oxidative stress levels decreased significantly after Pycnogenol supplementation, improving quality of life and helping to control signs and symptoms of menopause

"As evidenced by this study, Pycnogenol may arguably represent a very effective basic, daily dietary supplement for menopausal women due to its extended range of health benefits, including cardiovascular benefits and Pycnogenol's proven ability to lower blood pressure," says Dr. Gianni Belcaro, the lead researcher from Pescara University, Italy.

Results showed that not only did Pycnogenol improve menopausal signs and symptoms, but also decreased elevated levels of oxidative stress, as shown by capillary blood tests. Pycnogenol's ability to manage heart health is of particular significance as menopausal women live at elevated risk for cardiovascular disease.

This study confirms previous findings that Pycnogenol effectively improves perimenopausal signs and symptoms. A previous study in Taiwan investigated 200 mg of Pycnogenol in 200 perimenopausal women over a period of half a year and identified an improvement in most signs and symptoms. This study demonstrated Pycnogenol's ability to improve signs and symptoms not only with a smaller dosage of Pycnogenol but also over a shorter period of time.


'/>"/>

Contact: Katherine Davis
kdavis@mww.com
312-981-8549
MWW Group
Source:Eurekalert

Related biology news :

1. Pycnogenol (French maritime pine bark extract) shown to improve visible signs of aging in new study
2. Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan
3. ComCam Selected by ePortation on New Maritime Domain Awareness Project
4. ComCam Selected by ePortation on New Maritime Domain Awareness Project
5. Stevens and TNO to collaborate on maritime security
6. National Center for Secure and Resilient Maritime Commerce releases annual report
7. New ways to chart our maritime past
8. NOAA, Spain announce cooperative arrangement to preserve maritime underwater heritage
9. Ultrasound shown to exert remote control of brain circuits
10. Dictyostelium cells shown to lay breadcrumb trail as first step in multicellular formation
11. Twin nanoparticle shown effective at targeting, killing breast cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... prospective clinical study that demonstrates the accuracy of the FebriDx® test, a ... significant acute bacterial and viral respiratory tract infections by testing the body’s ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology: